公开(公告)号：US11421034B2

公开(公告)日：2022-08-23

申请号：US16646690

申请日：2018-09-12

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Katherine E. Lewis ,  Serena Kimi Perna ,  Michael Carleton ,  Ke Xu ,  Penny Phillips ,  Dimple Pandya ,  Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Janine Powers ,  Ernestine Lee

IPC: C07K16/28 ,  A61K47/69 ,  A61K47/64 ,  A61P35/00 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/395 ,  C12Q1/6886 ,  A61K39/00

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

公开(公告)号：US20210009697A1

公开(公告)日：2021-01-14

申请号：US16646690

申请日：2018-09-12

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Katherine E. Lewis ,  Serena Kimi Perna ,  Michael Carleton ,  Ke Xu ,  Penny Phillips ,  Dimple Pandya ,  Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Janine Powers ,  Ernestine Lee

IPC: C07K16/28 ,  A61K31/7068 ,  A61K31/513 ,  A61K39/395 ,  A61K31/337 ,  A61K47/69 ,  A61K47/64 ,  C12Q1/6886 ,  A61P35/00

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

公开(公告)号：US20230192870A1

公开(公告)日：2023-06-22

申请号：US17812592

申请日：2022-07-14

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Katherine E. Lewis ,  Serena Kimi Perna ,  Michael Carleton ,  Ke Xu ,  Penny Phillips ,  Dimple Pandya ,  Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Janine Powers ,  Ernestine Lee

IPC: C07K16/28 ,  A61K47/69 ,  A61K47/64 ,  A61P35/00 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/395 ,  C12Q1/6886

CPC classification number: C07K16/2866 ,  A61K47/6929 ,  A61K47/643 ,  A61P35/00 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/3955 ,  C07K16/2818 ,  C12Q1/6886 ,  A61K2039/507

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

公开(公告)号：US11572405B2

公开(公告)日：2023-02-07

申请号：US16768838

申请日：2019-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael Carleton ,  David Feltquate ,  Olivier De Henau ,  Timothy Patrick Reilly ,  Tian Chen ,  Ye Feng ,  Shu-Pang Ben Huang ,  Ming Zhou ,  Ramachandran Suresh

IPC: C07K16/24 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  G01N33/68 ,  A61K39/00

Abstract: Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.